Researchers revealed that Bruton tyrosine kinase inhibitors (BTKIs) preserved T-cell and CART19 functionality under persistent antigen exposure and further demonstrated that BTKI administration was a potential strategy for mitigating cytokine release syndrome after CART19 treatment.
[Cytotherapy]